HSK44459

DRUG6 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd., Xizang Haisco Pharmaceutical Co., Ltd

Conditions

Atopic Dermatitis (AD)Behcet's DiseaseHealthyIPFIdiopathic Pulmonary Fibrosis (IPF)Progressive Pulmonary Fibrosis

Phase 1

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK44459 in Healthy Subjects

CompletedNCT06858657

Haisco Pharmaceutical Group Co., Ltd.Healthy

Start: 2024-08-17End: 2024-12-20Updated: 2025-03-05

Phase 2

Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease

Not yet recruitingNCT06902428

Haisco Pharmaceutical Group Co., Ltd.Behcet's Disease

Start: 2025-03-24End: 2026-07-03Target: 120Updated: 2025-03-30

A Study for HSK44459 in Participants With Atopic Dermatitis

Active, not recruitingNCT06996912

Xizang Haisco Pharmaceutical Co., LtdAtopic Dermatitis (AD)

Start: 2025-05-22End: 2026-03-23Target: 150Updated: 2026-01-02

Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Not yet recruitingNCT07019090

Haisco Pharmaceutical Group Co., Ltd.Idiopathic Pulmonary Fibrosis (IPF)

Start: 2025-06-27End: 2027-01-19Target: 120Updated: 2025-06-13

Phase 3

Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis

Not yet recruitingNCT07503587

Haisco Pharmaceutical Group Co., Ltd.Progressive Pulmonary Fibrosis

Start: 2026-04-05End: 2029-03-01Target: 378Updated: 2026-03-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis

Not yet recruitingNCT07519070

Haisco Pharmaceutical Group Co., Ltd.IPF

Start: 2026-04-05End: 2028-12-30Target: 420Updated: 2026-04-09